Must Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Pharmacyclics: Is it Time to Take Profits?
Research - Pharmacyclics (PCYC) has been a long-term idea for us, and a profitable one at that. But since August when I last wrote about PCYC at length, there has been little in the way of headline grabbing developments. T
Premium
Amarin Climbs on Vascepa Partnership for China
Insights - The private pharmaceutical company Eddingpharm will pay Amarin Corp (AMRN) $15 million for rights to develop and commercialize Amarin’s prescription-grade fish oil pill, Vascepa, in China, Hong … Continue Reading
Read now
Investors Should be Paying Attention to Xencor
Insights - Xencor, Inc (XNCR) priced an equity financing on Wednesday morning, selling 7.5 million shares of common stock at $14.25 for gross proceeds of $106 million. … Continue Reading
Read now
It’s only Monday and Biopharma Deals are already Dominating the Newsflow
Insights - Healthcare investors will be well-aware of Valeant's (VRX) $10 billion acquisition of Salix Pharmaceuticals (SLXP), announced over the weekend, but Monday morning has already been crammed full of biotech dealflow. Here's a quick recap.
Read now
Our Weekly Healthcare Roundup
What Investors Should Know About Proposed (& Drastic) Changes to the FDA
Insights - A draft of the 21st Century Cures Act carries serious implications for biopharma. Longer exclusivity, a faster approval process, and even the chance to SELL some exclusivity for certain products.
Read now